In particular, when the tumor cells were co-cultured with hPBMCs and treated with TR0304 at a concentration of 100 nM, the secretion of IL-2 in the MDA-MB-231 and BT-549 co-cultures was, respectively, 45% and 60% higher (8780 pg/mL and 7230 pg/mL) when compared with the combination of Relatlimab + Atezolizumab (100 nM + 100 nM) (Figure 9A,B upper panels). The gene discussed is IL2; the disease is neoplasm.